| Chimeric antigen receptors based on single-domain antibodies, and methods of … |
2022-10-18 |
2022-12-08 |
|
| Anti-gpc3 chimeric antigen receptor and methods of use thereof |
2022-9-06 |
2023-3-09 |
|
| Modified immune cells expressing tlr receptors |
2022-8-18 |
2023-2-23 |
|
| Antibodies and chimeric antigen receptors targeting glypican-3 (gpc3) and … |
2022-8-18 |
2022-10-01 |
|
| Multispecific antigen binding proteins and methods of use thereof |
2022-8-10 |
2023-2-23 |
|
| Anti-cd33 antibodies and uses thereof |
2022-8-01 |
2023-2-02 |
|
| Antibodies against cll1 and constructs thereof |
2022-8-01 |
2023-2-02 |
|
| Mutant il-15 compositions and methods thereof |
2022-7-08 |
2023-2-09 |
|
| Interleukin-15 variants and uses thereof |
2022-7-08 |
2023-1-12 |
|
| Claudin18.2 binding moieties and uses thereof |
2022-6-19 |
2022-8-01 |
|
| Single domain antibodies and chimeric antigen receptors targeting bcma and … |
2022-6-13 |
2022-8-01 |
|
| Antibodies targeting afp peptide/mhc complexes and uses thereof |
2022-5-31 |
2022-12-08 |
|
| Methods of minimizing neurotoxicity associated with chimeric antigen receptor ( … |
2022-5-10 |
2022-11-17 |
|
| Chimeric antigen receptors targeting gpc3 and methods of use thereof |
2022-5-05 |
2022-11-03 |
|
| Chimeric cytokine receptors and uses thereof in cellular therapies |
2022-4-19 |
2022-10-27 |
|
| Fusion proteins and uses thereof |
2022-4-15 |
2022-10-20 |
|
| Engineered immune cells and uses thereof |
2022-4-02 |
2022-10-06 |
|
| Nef-containing t cells and methods of producing thereof |
2022-2-27 |
2022-4-01 |
|
| Engineered immune effector cells expressing exogenously introduced cytokines |
2022-2-25 |
2022-9-01 |
|
| Engineered cells and uses thereof |
2022-2-08 |
2022-8-18 |
|
| Sars-cov-2 binding molecules and uses thereof |
2022-1-28 |
2022-8-04 |
|
| Methods and compositions for depleting natural killer cells and uses thereof in … |
2021-12-14 |
2022-6-23 |
|
| BCMA-TARGETED CAR T-CELL THERAPY FOR MULTIPLE MYELOMA |
2021-12-03 |
2022-6-30 |
|
| Use of a chimeric co-stimulatory receptor for cell therapy |
2021-10-21 |
2022-4-28 |
|
| Polypeptides comprising a vaccine specific tcr and a chimeric antigen receptor … |
2021-10-21 |
2022-4-28 |
|
| T cell and antigen-presenting cell engagers and uses thereof |
2021-9-29 |
2022-4-07 |
|
| Engineered immunoresponsive cells and uses thereof |
2021-8-17 |
2022-2-24 |
|
| Cd22 binding molecules and uses thereof |
2021-7-16 |
2022-1-20 |
|
| CD19 binding molecules and uses thereof |
2021-7-16 |
2023-2-16 |
|
| Cd20 binding molecules and uses thereof |
2021-7-16 |
2022-1-20 |
|
| Multispecific chimeric antigen receptors and uses thereof |
2021-7-16 |
2022-1-20 |
|
| Engineering gamma delta t cells with interleukin-36 for immunotherapy |
2021-7-09 |
2022-1-13 |
|
| Methods of reducing graft rejection of allogeneic cell therapy |
2021-7-06 |
2022-1-13 |
|
| Claudin18.2 binding moieties and uses thereof |
2021-6-27 |
2021-8-31 |
|
| GENETIC ENGINEERING OF γδ T CELLS FOR IMMUNOTHERAPY |
2021-6-22 |
2021-12-30 |
|
| Activation induced cytokine production in immune cells |
2021-6-05 |
2021-12-09 |
|
| Compositions and methods for reducing host rejection of allogeneic cells using … |
2021-5-13 |
2023-3-22 |
|
| Compositions and methods for reducing graft rejection in allogeneic cell … |
2021-4-01 |
2021-10-07 |
|
| Neutralizing antibody of novel coronavirus SARS-CoV-2 and application thereof |
2021-3-22 |
2021-6-29 |
|
| Glypican-2-binding moieties, chimeric antigen receptors and uses thereof |
2021-3-12 |
2021-12-01 |
|
| Method for treating coronavirus by using ace-2-fc fusion protein |
2021-2-26 |
2021-9-02 |
|
| Anti-mesothelin chimeric antigen receptor (car) constructs and uses thereof |
2021-2-24 |
2021-4-29 |
|
| Nef-containing t cells and methods of producing thereof |
2021-1-18 |
2021-3-25 |
|
| Engineered cells and uses thereof |
2020-9-29 |
2020-11-30 |
|
| Method for treating coronavirus infections |
2020-7-24 |
2021-9-02 |
|
| Single-domain antibodies against lag-3 and uses thereof |
2020-7-23 |
2020-9-30 |
|
| Anti-cd47 antibodies that do not cause significant red blood cell agglutination |
2020-7-21 |
2020-9-30 |
|
| Anti-dll3 chimeric antigen receptors and uses thereof |
2020-7-17 |
2021-1-21 |
|
| Multispecific antigen binding proteins and methods of use thereof |
2020-7-01 |
2020-8-31 |
|
| Single-domain antibodies and variants thereof against pd-1 |
2020-6-29 |
2020-8-31 |
|
| Antibodies and variants thereof against tigit |
2020-6-29 |
2020-8-31 |
|
| Single-domain antibodies and variants thereof against tigit |
2020-6-22 |
2020-8-31 |
|
| Antibodies and variants thereof against pd-l1 |
2020-6-22 |
2020-8-31 |
|
| Multispecific chimeric receptors comprising an nkg2d domain and methods of use … |
2020-6-18 |
2020-8-31 |
|
| Engineered immune cells comprising a recognition molecule |
2020-5-15 |
2022-3-23 |
|
| Single-domain antibodies and variants thereof against pd-l1 |
2020-5-04 |
2020-6-30 |
|
| Engineered cells and uses thereof |
2020-4-22 |
2021-11-18 |
|
| Chimeric receptor polypeptides and uses thereof |
2020-1-14 |
2020-7-23 |
|
| Modified immune cells expressing flagellin polypeptide |
2020-1-03 |
2020-7-09 |
|
| Cd30-binding moieties, chimeric antigen receptors, and uses thereof |
2019-12-26 |
2022-5-12 |
|
| Anticoagulation factor XI active factor XIa antibody and its preparation method … |
2019-10-22 |
2022-3-25 |
|
| Single-domain antibodies against cd33 and constructs thereof |
2019-9-10 |
2020-3-19 |
|
| Co-receptor systems for the treatment of infectious diseases |
2019-7-12 |
2021-2-05 |
|
| Compositions and methods for increasing protein half-life in a serum |
2019-7-01 |
2019-10-31 |
|
| Single-domain antibodies and variants thereof against ctla-4 |
2019-4-03 |
2019-6-30 |
|
| MULTISPECIFIC CHIMERIC RECEIVERS COMPRISING AN NKG2D DOMAIN AND METHODS OF … |
2018-12-28 |
2021-9-28 |
|
| RECOMBINANT CELL FOR EVALUATING BIOACTIVITY OF ANTI-TNF-α DRUG, AND USE THEREOF |
2018-11-28 |
2019-6-06 |
|
| Dual targeting antigen binding molecule |
2018-9-29 |
2020-4-02 |
|
| Chimeric antibody immune effector cell junction and method of use thereof |
2018-6-27 |
2019-2-16 |
|
| Chimeric antigen receptor and use thereof |
2017-12-29 |
2023-1-31 |
2023-1-31 |
| Compositions and methods for increasing protein half-life in a serum |
2017-10-11 |
2020-4-29 |
|
| Human-cd123-targeting chimeric receptor ligand and application thereof |
2017-8-31 |
2019-7-25 |
|
| Chimeric antigen receptors targeting bcma and methods of use thereof |
2017-8-10 |
2023-4-04 |
2023-4-04 |
| Chimeric antigen receptors targeting bcma and methods of use thereof |
2017-8-10 |
2022-8-26 |
|
| Engineered mammalian cells for cancer therapy |
2017-1-26 |
2018-12-12 |
|
| High-affinity, high-specificity and higher-functionality anti-human PD-L1 … |
2016-12-25 |
2021-3-05 |
2021-3-05 |
| Receptores quiméricos multiespecíficos que compreendem um domínio nkg2d e … |
2018-12-28 |
2021-9-28 |
|
| Recepteurs d'antigene chimeriques ciblant bcma et leurs procedes d'utilisation |
2017-8-10 |
2023-4-04 |
2023-4-04 |